Akebia is a high-risk nephrology turnaround where Vafseo must scale fast enough to outrun Auryxia’s collapse, cash burn, debt-like obligations, and dilution risk.
Akebia Therapeutics, Inc. (AKBA) is a fully integrated, commercial-stage biopharmaceutical company dedicated to the development and commercialization of therapeutics for patients suffering from kidney disease.[1] The entity operates primarily within the specialty nephrology market, focusing on renal anemia and hyperphosphatemia.[2, 3] The business model is built around two commercialized products: Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, and Auryxia (ferric citrate), an oral iron-based phosphate binder and iron deficiency anemia treatment.[3]
The primary mechanism of revenue generation is net product sales within the United States, supplemented by international license, collaboration, and royalty revenues.[1, 3] Geographically, the United States remains the primary driver of commercial operations, while international markets are monetized through strategic out-licensing agreements.[1, 3] For instance, Averoa SAS possesses the exclusive rights to commercialize ferric citrate in the European Economic Area, Turkey, the United Kingdom, and parts of the Middle East, having received European Commission approval in June 2025.[1] In Japan, partnerships with Mitsubishi Tanabe Pharma Corporation and Torii Pharmaceutical Co., Ltd. generate milestones and royalty flows.[1]
Akebia's core commercial products are detailed in the table below:
| Product | Mechanism of Action | Target Indication / End Market | Primary Customers |
|---|---|---|---|
| Vafseo (vadadustat) [3] | Oral HIF-PH inhibitor that stabilizes HIF transcription factors to stimulate endogenous erythropoietin.[4, 5] | Anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months.[5, 6] | Large and medium dialysis organizations, independent dialysis clinics, and nephrology networks.[7, 8] |
| Auryxia (ferric citrate) [3] | Orally administered, iron-based phosphate binder and iron absorber.[3] | Hyperphosphatemia and iron deficiency anemia in adult CKD patients on dialysis.[3] | Dialysis patients and specialty renal pharmacies under contract with dialysis providers.[1, 3] |
Nephrologists and dialysis organizations select Akebia’s products over historical standard-of-care alternatives due to distinct clinical and operational parameters. Vafseo provides a once-daily oral administration alternative to injectable erythropoiesis-stimulating agents (ESAs) like darbepoetin alfa, which require intravenous or subcutaneous delivery.[5, 6, 9] In clinical studies, such as the post-hoc analysis of the INNO2VATE trials published in the Journal of the American Society of Nephrology, patients treated with vadadustat demonstrated a statistically significant reduction in a hierarchical composite endpoint of all-cause mortality and hospitalization compared to those receiving traditional ESAs.[9, 10]
Operationally, the medical community’s preference for Vafseo is driven by its integration into in-center observed dosing protocols, which significantly improves treatment adherence.[9, 11] Auryxia is preferred because its iron-based chemistry simultaneously controls serum phosphorus and delivers elemental iron, thereby reducing the cumulative pill burden of separate phosphate binders and oral or intravenous iron therapies.[3]
Akebia’s current corporate strategy is centered on transitioning its operational foundation from Auryxia, which faces intense generic competition, to the commercial acceleration of Vafseo.[2, 4] Vafseo was approved by the FDA on March 27, 2024, and commercial shipments commenced in the United States in January 2025.[1, 12] To drive rapid market penetration, the commercial team has secured supply contracts with dialysis providers covering nearly 100% of the U.S. dialysis patient pool, including major providers like DaVita, Inc., U.S. Renal Care (USRC), and Innovative Renal Care.[7, 8]
The core driver of Vafseo volume growth is the transition of clinics to observed dosing protocols.[9, 11] Adherence rates for patients in centers utilizing observed dosing protocols reached 86% to 91% in the first quarter of 2026, representing a massive improvement over the historical 75% adherence seen with daily home dosing.[9, 13] DaVita completed an initial 100-clinic operational pilot in late 2025 and is projected to initiate a wide operational transition to Vafseo in the second half of 2026, which is expected to accelerate adoption.[7, 11]
To build clinical support for Vafseo as the standard of care, Akebia is advancing two major post-marketing clinical trials:
| Trial Name | Phase | Design and Sample Size | Expected Timeline | Strategic Objective |
|---|---|---|---|---|
| VOCAL [9] | Phase IIIb [9] | Approximately 350 patients evaluating three-times-weekly (TIW) dosing vs. ESAs, including a red blood cell sub-study.[9, 14] | Topline data expected in Q4 2026.[9, 14] | Support the operational three-times-weekly clinical flow in standard U.S. dialysis centers.[9] |
| VOICE [9] | Phase IV [9] | Over 2,100 patients evaluated by USRC comparing TIW Vafseo vs. ESAs using a hierarchical composite of mortality and hospitalization.[9] | Topline data expected in early 2027.[9] | Establish real-world clinical and economic non-inferiority or superiority to displacement of ESAs.[5, 9] |
Akebia's pipeline initiatives focus on mid-to-early-stage clinical candidates in rare renal and acute indications.[2, 9] This includes praliciguat, an oral soluble guanylate cyclase (sGC) stimulator in Phase II clinical development for Focal Segmental Glomerulosclerosis (FSGS), aiming to enroll approximately 60 patients.[2, 9] Additionally, the company is advancing AKB-097, a next-generation, tissue-targeted complement inhibitor acquired from Q32 Bio Inc. in late 2025, which is scheduled to enter a Phase II open-label rare kidney disease basket study in late 2026 evaluating patients with IgA nephropathy, lupus nephritis, and C3 glomerulopathy.[9, 14] Lastly, AKB-9090, an internally developed oral molecule leveraging the company's hypoxia-inducible factor biology expertise, is undergoing Phase I evaluation in up to 70 healthy volunteers for acute kidney injury (AKI) associated with cardiac surgery, with topline data expected in early 2027.[2, 15]
Akebia's competitive moat is specialized but highly vulnerable. It relies primarily on complex distribution channels, regulatory barriers, and crystal-form intellectual property [16, 17]:
* Switching Costs: Once a dialysis organization transitions its clinical workflows, electronic health record tracking, and nursing protocols to support oral Vafseo observed dosing, the friction of reversing this setup back to injectable ESAs is high.[7, 11, 16]
* Regulatory Exclusivity & Reimbursement: Vafseo was granted Medicare's Transitional Drug Add-on Payment Adjustment (TDAPA) status under the End-Stage Renal Disease Prospective Payment System, effective January 1, 2025.[16] This status ensures a dedicated reimbursement adjustment until December 31, 2026, incentivizing initial clinic adoption.[16]
* Intellectual Property: While Vafseo's foundational compound patent (US8940773B2) is set to expire on June 26, 2027, the crystal form patent (US9987262B2) extends to November 14, 2034, creating a protective barrier of nearly seven years against generic vadadustat entry.[17] Additional method-of-use and composition patents, such as US Patent 11,324,734, provide further protection.[18]
Conversely, the competitive moat for Auryxia has fully eroded.[4] Akebia’s exclusive patent protection in the U.S. expired on March 20, 2025, allowing generic entrants to erode the product's historical pricing power and market share.[1, 3]
The domestic market opportunity for Vafseo is highly concentrated.[19] The U.S. chronic dialysis segment consists of approximately 550,000 patients, representing a stable, captive base of prospective users.[19] Spherix Global Insights and corporate tracking project that oral HIF-PH inhibitors will capture a meaningful share of this market, with Vafseo targeted to achieve a 10% market share of dialysis-related renal anemia treatment by the end of 2026.[19, 20]
However, Akebia’s long-term total addressable market (TAM) was severely constrained in early 2026.[1] Following a Type C meeting with the FDA, the company failed to align on the design of the VALOR clinical trial, which was intended to expand Vafseo’s label to include non-dialysis dependent CKD patients.[1] Consequently, Akebia abandoned the VALOR trial and will not pursue a non-dialysis label, permanently closing off a multi-billion-dollar market segment in the United States.[1, 8]
The oral renal anemia segment is highly competitive.[12] Vafseo’s direct competitor is GlaxoSmithKline’s (GSK) Jesduvroq (daprodustat), which was approved by the FDA in February 2023.[12, 21] Like Vafseo, Jesduvroq is restricted strictly to patients undergoing dialysis due to class-wide safety concerns in non-dialysis settings, and both products carry a prominent boxed warning highlighting the risk of major adverse cardiovascular events (MACE) and death.[6, 8, 12]
Akebia is currently holding its ground in the oral market through targeted positioning.[21] Vafseo holds a slight advantage: it is approved for patients on dialysis for at least three months, whereas Jesduvroq requires four months of dialysis.[21, 22] Additionally, Jesduvroq’s label includes a warning regarding hospitalizations for heart failure, a risk that is not explicitly warned against on Vafseo’s packaging.[21]
The primary competitive threat, however, remains legacy biologics.[19] Amgen's Aranesp (darbepoetin alfa) and Epogen still command the vast majority of dialysis anemia spending.[19] Transitioning these clinics to oral alternatives requires proving both clinical superiority and operational cost-efficiency to highly consolidated dialysis organizations.[9, 13, 16]
Akebia reported its financial results for the first quarter of 2026 on May 7, 2026.[2, 23] The results show that the generic erosion of Auryxia is progressing faster than Vafseo’s initial launch ramp.[4, 24]
A summary of the quarterly financial results is presented below:
| Financial Metric | Q1 2026 Actual | Q1 2025 Actual | Year-over-Year Change | Analyst Consensus | Performance vs. Consensus |
|---|---|---|---|---|---|
| Total Revenues | \$53.54M [4, 25] | \$57.34M [4] | -6.61% [25, 26] | \$54.89M [24, 25] | Missed by 2.46% (-\$1.35M) [24, 25] |
| Vafseo Product Revenue | \$15.80M [2, 4] | \$12.00M [2, 23] | +31.68% [24] | N/A | N/A |
| Auryxia Product Revenue | \$36.19M [2, 4] | \$43.80M [2, 23] | -17.37% [24] | N/A | N/A |
| Cost of Goods Sold (COGS) | \$12.30M [11, 23] | \$7.60M [23, 27] | +61.84% [23, 27] | N/A | N/A |
| R&D Expenses | \$14.80M [2, 23] | \$9.80M [2, 23] | +51.02% [2, 23] | N/A | N/A |
| SG&A Expenses | \$30.40M [2, 23] | \$25.70M [2, 23] | +18.29% [2, 23] | N/A | N/A |
| Net Income (Loss) | (\$9.05M) [4, 28] | \$6.11M [4, 28] | Reversal to Loss [4] | N/A | N/A |
| Earnings Per Share (EPS) | (\$0.03) [4, 11] | \$0.03 [4, 11] | Reversal to Loss [4] | (\$0.01) [25, 29] | Missed by \$0.02 (200% Miss) [25, 29] |
The Q1 2026 performance highlights several key trends for investors:
* Vafseo Progress: Vafseo net product revenues rose to $15.80 million, supported by a 60% quarter-over-quarter increase in patients on therapy and a 28% increase in active prescribers.[2, 23] However, gross margins were impacted by a rise in COGS to $12.30 million, primarily due to Auryxia inventory write-downs from excess, obsolescence, and scrap following its patent expiration.[11, 23] Vafseo-specific COGS remained low because it utilized pre-launch inventory previously expensed as R&D, but COGS is expected to rise once this low-cost inventory is depleted.[13, 23]
* Auryxia Collapse: Net product revenues for Auryxia fell to $36.19 million, down from $43.80 million in Q1 2025.[2, 23] Teva’s generic version entered the market on March 11, 2026, which is expected to accelerate volume and pricing erosion.[4]
* Operational Spend Ramps: R&D expenses rose to $14.80 million due to active Phase II praliciguat and Phase I AKB-9090 clinical trials, while SG&A expenses rose to $30.40 million due to Vafseo launch support and hiring.[2, 23] This operational cash burn drove a quarterly operating cash outflow of $21.21 million, leaving the company with $162.64 million in cash and cash equivalents.[4]
Management updated its outlook, warning that Auryxia sales will contract significantly through 2026.[2] While the press release stated that cash resources should fund the current operating plan for "at least two years," the formal Q1 10-Q filing was more conservative, noting that cash is sufficient to fund the operating plan for "at least twelve months" and is highly dependent on achieving Vafseo revenue targets.[4] Underperformance of Vafseo could impact future going-concern assessments.[4]
Following the announcement, Akebia’s stock dropped by 18.92% in pre-market trading, falling from its previous close of $1.48 to $1.20, and continued to decline.[24, 25] Analysts lowered their consensus FY2026 revenue projections from $222.50 million to $206.60 million and increased their projected EPS loss from -$0.056 to -$0.17.[30, 31] The projected breakeven date was also pushed back from 2026 to 2028.[31] Despite these near-term revisions, analysts maintained a bullish long-term stance, with price targets ranging from $3.00 to $6.00 (averaging $4.20 to $4.67).[24, 30, 32]
Based on the current stock price of $0.92 USD (as of June 10, 2026) and 267,898,415 shares outstanding, Akebia’s equity valuation is summarized below [33, 34]:
The company's historical revenue performance over the past five years is detailed in the table below:
| Fiscal Year | Total Revenues | YoY Revenue Change | Performance Narrative |
|---|---|---|---|
| 2021 [35, 36] | \$211.65M [35, 36] | -28.17% [35, 36] | Impacted by slowing Auryxia volumes and operational restructuring.[36] |
| 2022 [35, 36] | \$292.48M [35, 36] | +38.19% [35, 36] | Driven by transient royalty flows and post-merger adjustments.[36] |
| 2023 [35, 36] | \$194.62M [35, 36] | -33.46% [35, 36] | Impacted by regulatory delay of Vafseo and lower inventory shipments.[21, 36] |
| 2024 [35, 36] | \$160.18M [35, 36] | -17.70% [35, 36] | Impacted by pre-launch distribution costs and declining Auryxia demand.[1, 36] |
| 2025 [35, 36] | \$236.20M [35, 36] | +47.46% [35, 36] | Driven by the initial commercial launch of Vafseo in the United States.[9, 36] |
This historical trend highlights the volatility in Akebia's performance, resulting in a five-year compound annual growth rate (CAGR) from 2020 ($294.64 million) to 2025 ($236.20 million) of -4.33%.[35, 36] This negative growth underscores the terminal contraction of Auryxia before Vafseo’s launch and explains why the stock trades at a low valuation of approximately 1.0x enterprise value to sales.[4, 37]
Akebia’s operational transition exposes the company to several critical risks. The central risk is execution speed: if dialysis organizations delay integrating Vafseo into their clinical protocols, the company may exhaust its remaining cash reserves.[4] This execution risk is heightened by the cancellation of the VALOR trial, which limits Vafseo's addressable market to dialysis patients and increases its reliance on high-volume clinics.[1, 19]
+-----------------------------------------------------------------------------------+
| CORE OPERATIONAL RISKS |
| |
| |
| Slower protocol transition at DaVita or USRC clinics [7, 11] |
| |
| |
| Rapid market share capture by GSK's Jesduvroq or legacy ESAs [12, 19] |
| |
| |
| Consolidated pricing power of DaVita & USRC [7, 19] |
| |
| |
| Over $210M in structured liabilities and impending BlackRock principal [4] |
+-----------------------------------------------------------------------------------+
The highly consolidated nature of the U.S. dialysis sector is a key challenge.[19] A large portion of the market is controlled by DaVita and USRC, giving these providers significant bargaining power to demand high rebates and discounts.[7, 19] If competitors like GSK lower prices for Jesduvroq, Akebia’s margins could be compressed.[12, 19] This concentration risk is compounded by Vafseo's boxed warning, which may limit adoption among safety-conscious physicians.[6, 8, 21]
The company’s capital structure carries significant liabilities.[4] Beyond the $48.89 million senior secured BlackRock term loan, which requires principal payments starting December 31, 2026, Akebia has several structured liabilities [4, 38, 39]:
* CSL Vifor Working Capital Fund (WCF) Repayment: Akebia must repay the $40.00 million fund through tiered royalties ranging from 8% to 14% on net Vafseo sales starting July 1, 2025.[40] This repayment is subject to strict minimum true-up milestones [40]:
* $10.00 million by May 31, 2026.[40]
* $20.00 million cumulative by May 31, 2027.[40]
* $40.00 million cumulative by May 31, 2028.[40]
If royalty payments fall short of these thresholds, Akebia must pay the difference in cash, which would accelerate its cash burn.[40]
* Settlement and Royalty Liabilities: The balance sheet includes $70.24 million in settlement royalties and $51.82 million in royalty-sale liabilities, which act as long-term cash drains.[4]
Investors should monitor several key indicators:
* Slower-than-expected growth in Vafseo prescription numbers or delay in DaVita's transition in the second half of 2026.[11, 23]
* A failure to meet the $10.00 million WCF royalty true-up milestone by May 31, 2026, requiring a cash payment to CSL Vifor.[40]
* A rapid decline in Auryxia revenues to below $25.00 million per quarter, suggesting faster generic erosion than expected.[2, 4]
The investment thesis would be significantly impaired if:
* Vafseo peak market share is capped at less than 8% of U.S. dialysis patients due to safety concerns or competitive pressure.[12, 19]
* The company undergoes significant equity dilution, such as issuing the full 500 million authorized shares, which would dilute existing shareholders.[28, 34]
* Liquid assets fall below $50.00 million, triggering covenant breaches under the BlackRock loan agreement or a going-concern warning.[4, 41]
This five-year scenario analysis projects Akebia's performance from the end of FY2025 to the end of FY2030. The projections are calculated relative to the current share price of $0.92 USD.[33]
+-----------------------------------------------------------------------------+
| 5-YEAR VALUE TRAJECTORY (USD) |
| |
| $4.00 | High Case: $3.60 |
| $3.00 | / |
| $2.00 | / |
| $1.00 |------------------------------------------*---- Base Case: $1.12 |
| $0.00 |________________________________________/______ Low Case: $0.09 |
| Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 |
+-----------------------------------------------------------------------------+
Vafseo achieves rapid adoption, capturing 25% of the U.S. dialysis market by 2030, driven by swift integration across DaVita, USRC, and independent clinics.[7, 11, 19] Observed dosing protocols minimize compliance issues, and post-marketing trials (VOCAL/VOICE) establish Vafseo as clinically superior to standard ESAs.[9, 14] Auryxia’s erosion is slower than feared due to favorable pricing contracts, while international royalty streams from Europe and Japan grow robustly.[1]
* Operating Assumptions: Year 5 revenues reach $400.00 million (representing an 11.11% CAGR from FY2025's $236.20 million).[35, 36] Net margins reach 15.00%, generating $60.00 million in net income.
* Capital Assumptions: Share count increases moderately to 300.00 million due to option exercises.[10, 34]
* Valuation Assumptions: A P/E multiple of 18.0x is applied, reflecting strong cash flow and an advancing pipeline.[9, 14]
* Valuation Bridge:
$\text{Market Capitalization} = \$60.00\text{M Net Income} \times 18.0\text{ P/E} = \$1,080.00\text{M}$ $\text{Implied Year 5 Share Price} = \frac{\$1,080.00\text{M}}{300.00\text{M shares}} = \$3.60\text{ USD}$
* Projected Total Return: +291.30% (31.37% annualized).
Vafseo achieves steady market share gains, capturing 12% of the U.S. dialysis market by 2030, with DaVita completing its clinical protocol rollout but at lower negotiated average selling prices.[11, 19] Auryxia sales contract sharply, dropping to $15.00 million due to intense competition from Teva and other generic entrants.[2, 4] Pipeline trials progress slowly, requiring steady R&D funding.[2, 23] Dilution increases as the company utilizes its expanded share authorization to fund capital requirements.[28, 34]
* Operating Assumptions: Year 5 revenues reach $280.00 million (a 3.46% CAGR from FY2025).[35, 36] Net margins reach 10.00%, generating $28.00 million in net income.
* Capital Assumptions: Share count increases to 350.00 million due to moderate capital raises.[28, 34]
* Valuation Assumptions: A P/E multiple of 14.0x is applied, aligned with the specialty generic drug sector.[37]
* Valuation Bridge:
$\text{Market Capitalization} = \$28.00\text{M Net Income} \times 14.0\text{ P/E} = \$392.00\text{M}$ $\text{Implied Year 5 Share Price} = \frac{\$392.00\text{M}}{350.00\text{M shares}} = \$1.12\text{ USD}$
* Projected Total Return: +21.74% (4.01% annualized).
Vafseo adoption plateaus at 5% of the market due to intense competition from GSK and entrenched ESAs.[12, 19] Auryxia sales fall to near-zero as multiple generics enter.[4] The cancellation of the VALOR trial prevents any non-dialysis growth.[1] Akebia is forced to repeatedly issue equity to fund its high R&D and SG&A expenses, as well as the cash true-up obligations under the CSL Vifor WCF agreement, diluting existing shareholders heavily.[2, 28, 40]
* Operating Assumptions: Year 5 revenues drop to $150.00 million (a -8.68% CAGR from FY2025).[35, 36] Net margin is negative at -10.00% (a net loss of -$15.00 million).
* Capital Assumptions: Share count increases to 480.00 million due to heavy dilutive equity issuance under the expanded 500 million share authorization.[28, 34]
* Valuation Assumptions: A distressed 0.30x Price-to-Sales (P/S) multiple is applied.[35, 37]
* Valuation Bridge:
$\text{Market Capitalization} = \$150.00\text{M Revenue} \times 0.30\text{ P/S} = \$45.00\text{M}$ $\text{Implied Year 5 Share Price} = \frac{\$45.00\text{M}}{480.00\text{M shares}} = \$0.09\text{ USD}$
* Projected Total Return: -90.22% (-37.28% annualized).
The projected share price trajectories in USD are detailed below:
| Year | High Case (\$3.60 Exit) | Base Case (\$1.12 Exit) | Low Case (\$0.09 Exit) |
|---|---|---|---|
| Year 0 (2025) [33] | \$0.92 USD | \$0.92 USD | \$0.92 USD |
| Year 1 (2026) | \$1.15 USD | \$0.94 USD | \$0.60 USD |
| Year 2 (2027) | \$1.50 USD | \$0.98 USD | \$0.40 USD |
| Year 3 (2028) | \$2.00 USD | \$1.02 USD | \$0.25 USD |
| Year 4 (2029) | \$2.75 USD | \$1.07 USD | \$0.15 USD |
| Year 5 (2030) | \$3.60 USD | \$1.12 USD | \$0.09 USD |
The scenario parameters are summarized in the table below:
| Scenario | Revenue / Metric (Year 5) | Margin / Earnings Assumption | Valuation Multiple | Current Price | Implied Price | 5-Year Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | \$400.00M | 15.00% Net Margin (\$60.00M NI) | 18.0x P/E | \$0.92 USD | \$3.60 USD | +291.30% | 31.37% | 20.00% |
| Base Case | \$280.00M | 10.00% Net Margin (\$28.00M NI) | 14.0x P/E | \$0.92 USD | \$1.12 USD | +21.74% | 4.01% | 55.00% |
| Low Case | \$150.00M | -10.00% Net Margin (-\$15.00M NL) | 0.30x P/S | \$0.92 USD | \$0.09 USD | -90.22% | -37.28% | 25.00% |
Applying the subjective probability weights to the projected share prices yields the following expected valuation:
$\text{Expected Share Price} = (\$3.60 \times 0.20) + (\$1.12 \times 0.55) + (\$0.09 \times 0.25) = \$0.72 + \$0.616 + \$0.0225 = \$1.36\text{ USD}$
This probability-weighted target of $1.36 USD implies a potential upside of 47.83% from the current price of $0.92 USD, indicating that the potential returns from a successful Vafseo launch offset the significant downside risks.[33]
ASYMMETRIC RISK-REWARD PROFILE
To evaluate the non-financial characteristics of Akebia, the company is rated on ten qualitative dimensions on a scale of 1 to 10.
Combining these dimensions yields a blended qualitative score of 4.2 / 10, indicating that Akebia is a high-risk, speculative asset that requires strong commercial execution to achieve long-term viability.
Note: This scorecard represents an independent qualitative evaluation and does not constitute financial advice or an investment recommendation.
SPECULATIVE TURNAROUND PROSPECT
Akebia Therapeutics is at a critical juncture, with its investment thesis depending on whether Vafseo can scale rapidly enough to offset the decline of Auryxia while the company manages a leveraged balance sheet.[2, 4]
In summary, Akebia represents a speculative turnaround story. If Vafseo achieves widespread adoption within major dialysis organizations, the stock offers significant recovery potential from its current depressed levels.[9, 24] However, if launch execution falters or structured liabilities trigger cash strains, shareholders face significant downside risks.[4, 28]
Note: This analysis is for educational and research purposes only and does not constitute financial advice.
HIGH-RISK SPECULATIVE TURNAROUND
Akebia is currently in a bearish technical trend, trading at $0.90 to $0.92 USD, which is significantly below its 50-day simple moving average of $0.988 USD and its 200-day simple moving average of $1.155 USD.[33, 43] The stock has been under pressure following the market’s negative reaction to the Q1 2026 earnings miss and the dilutive share authorization proposal.[4, 24, 28] While intermediate indicators like the RSI (37.6) and the Stochastic Oscillator suggest the stock is hovering near oversold levels, any near-term recovery will depend on Vafseo sales demonstrating stronger momentum in upcoming quarters.[2, 43]
BEARISH TREND DOMINATES
View Akebia Therapeutics, Inc. (AKBA) stock page
Loading the interactive version of this report…